Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • TA228
  • Published: 
Download guidance (PDF)

6 Related NICE guidance

Published

  • Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. NICE technology appraisal guidance 171 (2009). Available from www.nice.org.uk/guidance/TA171

  • Bortezomib monotherapy for relapsed multiple myeloma. NICE technology appraisal guidance 129 (2007). Available from www.nice.org.uk/guidance/TA129

Under development

NICE is developing the following guidance (details available from www.nice.org.uk):

  • Denosumab for the treatment of bone metastases from solid tumours and multiple myeloma. NICE technology appraisal guidance (publication expected June 2012).

  • National Institute for Health and Care Excellence (NICE)